Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies

Vet World Vol.17 May-2024 Article - 15

Review Article

Veterinary World, 17(5): 1052-1072

https://doi.org/10.14202/vetworld.2024.1052-1072

Tiago Ferreira^1,2,3,4, Ana I. Faustino-Rocha^1,2,5,6, Vítor M. Gaspar⁴, Rui Medeiros^3,7,8,9,10, João F. Mano⁴, and Paula A. Oliveira^1,2

1. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.
2. Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), UTAD, 5000–801 Vila Real, Portugal.
3. Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto. CCC), 4200–072 Porto, Portugal.
4. Department of Chemistry, Aveiro Institute of Materials (CICECO), University of Aveiro, Campus Universitário de Santiago, 3810–193, Aveiro, Portugal.
5. Department of Zootechnics, School of Sciences and Technology, University of Évora, Évora 7004-516, Portugal.
6. Comprehensive Health Research Center, 7004–516 Évora, Portugal.
7. Faculty of Medicine of the University of Porto, 4200–319 Porto, Portugal.
8. Department of Research, Portuguese League against Cancer-Regional Nucleus of the North (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), 4200–177 Porto, Portugal.
9. Virology Service, IPO Porto, 4200-072 Porto, Portugal.
10. Biomedical Research Center (CEBIMED), Faculty of Health Sciences, Fernando Pessoa University, Porto 4249-004, Portugal.

Chronic inflammation plays a crucial role in carcinogenesis. High levels of serum prostaglandin E2 and tissue overexpression of cyclooxygenase-2 (COX-2) have been described in breast, urinary, colorectal, prostate, and lung cancers as being involved in tumor initiation, promotion, progression, angiogenesis, and immunosuppression. Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for several medical conditions to not only decrease pain and fever but also reduce inflammation by inhibiting COX and its product synthesis. To date, significant efforts have been made to better understand and clarify the interplay between cancer development, inflammation, and NSAIDs with a view toward addressing their potential for cancer management. This review provides readers with an overview of the potential use of NSAIDs and selective COX-2 inhibitors for breast cancer treatment, highlighting pre-clinical in vitro and in vivo studies employed to evaluate the efficacy of NSAIDs and their use in combination with other antineoplastic drugs.

Keywords: breast cancer, chemoprevention, COX-2, cyclooxygenase, experimental studies, NSAIDs.

How to cite this article: Ferreira T, Faustino-Rocha AI, Gaspar VM, Medeiros R, Mano JF, and Oliveira PA (2024) Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies, Veterinary World, 17(5): 1052–1072.

Received: 2023-11-02 Accepted: 2024-04-19 Published online: 2024-05-15

Corresponding author: Tiago Ferreira and Paula A. Oliveira E-mail: tiagoterras55@gmail.com and pamo@utad.pt

DOI: 10.14202/vetworld.2024.1052-1072

Copyright: Ferreira, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.